Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Piperazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 1/20 | 0.67 |
| ▸ | MAPT | P10636 | 1/20 | 0.67 |
| ▸ | PDE4A | P27815 | 1/20 | 0.67 |
| ▸ | KDR | P35968 | 1/20 | 0.67 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13671434 | 1.00 | HIF1A (0.67) | HIF1AMAPTPDE4AKDRCXCR4 | |
| SCHEMBL2343047 | 1.00 | — | — | |
| SCHEMBL9614403 | 0.94 | HIF1A (0.56) | HIF1AMAPTPDE4AKDRCXCR4 | |
| SCHEMBL26047 | 0.94 | — | — | |
| Methane SCHEMBL18191054 | 0.89 | HIF1A (0.50) | HIF1AMAPTPDE4AKDRCXCR4 | |
| SCHEMBL4733483 | 0.89 | — | — | |
| SCHEMBL5616852 | 0.89 | HIF1A (0.50) | HIF1AMAPTPDE4AKDRCXCR4 | |
| SCHEMBL4273750 | 0.89 | — | — | |
| Iodide SCHEMBL19272496 | 0.89 | — | — | |
| Bromide SCHEMBL5898349 | 0.89 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11202784-B2 | Use of glucocorticoid receptor antagonists in combination with glucocorticoids to treat adrenal insufficiency | CORCEPT THERAPEUTICS, INC. (US) | 2021-12-21 | — | — | US | disclosed |
| US-20200206243-A1 | USE OF GLUCOCORTICOID RECEPTOR ANTAGONISTS IN COMBINATION WITH GLUCOCORTICOIDS TO TREAT ADRENAL INSUFFICIENCY | CORCEPT THERAPEUTICS, INC. | 2020-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200206243-A1 | USE OF GLUCOCORTICOID RECEPTOR ANTAGONISTS IN COMBINATION WITH GLUCOCORTICOIDS TO TREAT ADRENAL INSUFFICIENCY | CRH, MC2R, NR3C2 | HIF1A 2492/4885MAPT 4505/4885PDE4A 632/4885 |
| US-11202784-B2 | Use of glucocorticoid receptor antagonists in combination with glucocorticoids to treat adrenal insufficiency | NR3C2, MC2R, NR3C1 | HIF1A 3026/4885MAPT 4070/4885PDE4A 441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.